61 results
8-K
EX-99.1
AXSM
Axsome Therapeutics Inc
27 Mar 19
Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Major Depressive Disorder
7:05am
Axsome’s commitment to developing novel medicines that have the potential to significantly improve the lives of patients living with serious CNS … available therapy. Breakthrough Therapy designation provides an organizational commitment involving senior managers from the FDA, more intensive FDA
8-K
EX-99.1
AXSM
Axsome Therapeutics Inc
5 Aug 20
Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-12 for the Treatment of Narcolepsy
7:05am
agitation. These designations exemplify our commitment to developing potentially life-changing medicines for patients with difficult-to-treat CNS … provides an organizational commitment involving senior managers from the FDA, more intensive FDA guidance on an efficient drug development program
S-8
EX-99.3
AXSM
Axsome Therapeutics Inc
11 May 20
Registration of securities for employees
5:12pm
share of the Company Stock and represents the Company’s commitment to issue one share of Company Stock at a future date, subject to the terms … into a “same day sale” commitment with a broker-dealer that is a member of the Financial Industry Regulatory Authority (a “FINRA Dealer”) whereby you
8-K/A
EX-99.1
ai9be5kgm8 pm
22 Sep 20
Axsome Therapeutics Announces Expedited Development of AXS-12 for the Treatment of Narcolepsy Based on FDA Breakthrough Therapy Meeting
12:00am
8-K
EX-99.1
giha 38hj6
21 Sep 20
Axsome Therapeutics Announces Expedited Development of AXS-12 for the Treatment of Narcolepsy Based on FDA Breakthrough Therapy Meeting
7:10am
S-8
EX-99.4
urapiul5k4d
11 May 20
Registration of securities for employees
5:12pm
8-K
EX-99.1
pplzoa3 g8vj7at
11 Oct 23
Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors
5:03pm
8-K
EX-99.1
acilxh6c7
16 Sep 21
Other Events
7:05am
8-K
EX-99.1
99xywb
30 Jan 19
Topline results anticipated in 2Q 2019
7:06am
8-K
EX-99.1
ftpwlqjh 1fdp
18 Oct 21
Entry into a Material Definitive Agreement
7:05am
8-K
EX-99.1
824rw3oc
29 Sep 20
Axsome Therapeutics Announces $225 Million Term Loan Facility with Hercules Capital
7:06am
8-K
EX-99.1
7vgedd54y rx
4 Mar 19
Other Events
7:07am
8-K
EX-99.2
mcg65rpbfwvv6c 87
28 Mar 22
Axsome Therapeutics to Acquire Sunosi® from Jazz Pharmaceuticals, Expanding Axsome’s Leadership in Neuroscience
8:00am
8-K
EX-99.1
sjd t22b8454ova7
26 Jun 20
Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Alzheimer’s Disease Agitation
7:05am